Feature|Articles|September 11, 2023
- Pharmaceutical Executive: September 2023
- Volume 43
- Issue 9
Ahead of the Curve: Pharm Exec Profiles Five Recent Drug Launches
Pharm Exec’s latest selections of notable biopharma brand launches—some with novel preemptive approaches—highlight products that are paving uncharted paths across a diverse disease landscape.
Advertisement
Follow the links below to read about each product:
Selections were made by Pharmaceutical Executive's editorial staff, with close input from Editorial Advisory Board members.
Articles in this issue
over 2 years ago
Pharmaceutical Executive, September 2023 Issue (PDF)over 2 years ago
A New Era of Ethical Leadershipover 2 years ago
Survival Story: Enhertuover 2 years ago
Gut Instinct: Rebyotaover 2 years ago
Delaying Disease Onset: Tzieldover 2 years ago
New Beginnings: Sunlencaover 2 years ago
A Heartfelt Solution: Camzyosalmost 3 years ago
Fortifying Defenses Pre-Patent Cliffalmost 3 years ago
New Product Planning: The Function's Evolution in Pharmaalmost 3 years ago
No Rate Relief in Sight for BiotechAdvertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on PharmExec
1
Beyond JAK Inhibitors: Biologics Signal a New Era in Alopecia Areata
2
Pharma M&A Roundup: Incyte to Acquire Vega Therapeutics, Galmed Pharmaceuticals to Acquire Colospan, Johnson & Johnson Acquires Firefly Bio
3
Chai Discovery Enters License Agreement with Pfizer to Accelerate Drug Discovery with AI
4
U.S. Supreme Court Unanimously Votes in Favor of Hikma in Case Against Amarin: Report
5